Kinesin-1 (also known as conventional kinesin or KIF5) is a microtubule-based motor protein that transports cargo along axonal and dendritic pathways. First identified in 1985 as a force-generating protein involved in organelle transport, kinesin-1 has emerged as a critical regulator of neuronal function, responsible for the long-range transport of synaptic components, mitochondria, and signaling molecules [1].
Kinesin-1 is essential for neuronal health, and dysfunction in kinesin-mediated transport is implicated in multiple neurodegenerative diseases, including Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS). The protein functions as a molecular motor, using ATP hydrolysis to generate movement along microtubule tracks, carrying vital cargo from the cell body to synaptic terminals.
| Kinesin-1 (KIF5) | |
|---|---|
| Full Name | Kinesin-1 Heavy Chain |
| Gene | KIF5A, KIF5B, KIF5C |
| UniProt ID | [P33175](https://www.uniprot.org/uniprot/P33175) (KIF5A) |
| Protein Size | 963 amino acids (KIF5A) |
| Protein Family | Kinesin motor protein family |
| Chromosomal Location | 12q13.3 (KIF5A) |
| Subcellular Location | Cytoskeleton, axonal and dendritic compartments |
| Associated Disease | ALS, Hereditary spastic paraplegia, AD, PD |
Kinesin-1 has a distinctive structure optimized for movement along microtubules:
| Domain | Function | Key Features |
|---|---|---|
| Motor head | Microtubule binding, force generation | ATPase cycle drives stepping |
| Neck | Dimerization, processive movement | Enables hand-over-hand walking |
| Stalk | Coiled-coil, cargo binding | Contains binding sites for adaptors |
| Tail | Cargo attachment, regulation | Kinesin light chain interaction |
Kinesin-1 undergoes dramatic conformational changes during its transport cycle:
Kinesin-1 is the primary motor for anterograde axonal transport [2]:
Kinesin-1 moves cargo through a processive "hand-over-hand" mechanism:
Kinesin-1-mediated transport is severely impaired in AD [4]:
Kinesin-1 dysfunction contributes to AD through multiple mechanisms:
Kinesin-1 dysfunction is implicated in PD pathogenesis [6]:
Kinesin-1 interacts with α-synuclein in PD [7]:
Kinesin-1 dysfunction particularly affects dopaminergic neurons:
Kinesin-1 mutations are linked to ALS and related disorders [8]:
ALS-related kinesin-1 mutations cause:
Kinesin-1 mutations are a major cause of hereditary spastic paraplegia (HSP) [9]:
| Approach | Agent | Target | Status |
|---|---|---|---|
| Microtubule stabilizers | Taxol, EpoD | Microtubules | Preclinical |
| Kinesin activators | Small molecule screens | Kinesin-1 | Investigational |
| Transport enhancers | Ciliary neurotrophic factor | Signaling pathways | Clinical trials |
| Gene therapy | AAV-KIF5 delivery | Kinesin-1 expression | Preclinical |
Vale RD, et al. "Identification of a novel force-generating protein, kinesin." Cell. 1985. ↩︎
Hirokawa N, et al. "Kinesin superfamilies: molecular properties and functions." Nat Rev Neurosci. 1998. ↩︎
Diefenbacher M, et al. "Kinesin-1 function in mitochondrial transport." J Cell Biol. 2020. ↩︎
Morfini GA, et al. "Kinesin dysfunction in Alzheimer's disease." J Neurosci. 2009. ↩︎
Wang S, et al. "Kinesin-1 and tau pathology in AD." J Neurosci. 2023. ↩︎
Zhang Y, et al. "Kinesin-1 dysfunction in Parkinson's disease models." Cell Rep. 2021. ↩︎
Xie Z, et al. "Kinesin-1 mediates α-synuclein toxicity." Nat Neurosci. 2022. ↩︎
Günther R, et al. "Kinesin-1 mutations and ALS." Neurology. 2005. ↩︎
Yang L, et al. "Kinesin-1 mutations in hereditary spastic paraplegia." Brain. 2021. ↩︎
Park J, et al. "Kinesin-1 targeted drug delivery across BBB." Adv Drug Deliv Rev. 2024. ↩︎